368 related articles for article (PubMed ID: 22850692)
1. Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation.
Herbrecht R; Caillot D; Cordonnier C; Auvrignon A; Thiébaut A; Brethon B; Michallet M; Mahlaoui N; Bertrand Y; Preziosi P; Ruiz F; Gorin NC; Gangneux JP
J Antimicrob Chemother; 2012 Nov; 67(11):2731-8. PubMed ID: 22850692
[TBL] [Abstract][Full Text] [Related]
2. Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study.
Candoni A; Caira M; Cesaro S; Busca A; Giacchino M; Fanci R; Delia M; Nosari A; Bonini A; Cattaneo C; Melillo L; Caramatti C; Milone G; Scime' R; Picardi M; Fanin R; Pagano L;
Mycoses; 2014 Jun; 57(6):342-50. PubMed ID: 24373120
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
[TBL] [Abstract][Full Text] [Related]
4. Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease.
Cornely OA; Maertens J; Bresnik M; Ebrahimi R; Dellow E; Herbrecht R; Donnelly JP
Mycoses; 2011 Sep; 54(5):e449-55. PubMed ID: 21039936
[TBL] [Abstract][Full Text] [Related]
5. European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies.
Hoenigl M; Strenger V; Buzina W; Valentin T; Koidl C; Wölfler A; Seeber K; Valentin A; Strohmeier AT; Zollner-Schwetz I; Raggam RB; Urban C; Lass-Flörl C; Linkesch W; Krause R
J Antimicrob Chemother; 2012 Aug; 67(8):2029-33. PubMed ID: 22566591
[TBL] [Abstract][Full Text] [Related]
6. Pre-emptive diagnosis and treatment of fungal infections--evaluation of a single-centre policy.
Schneider T; Halter J; Heim D; Passweg J; Stern M; Tichelli A; Weisser M; Gerull S
Clin Microbiol Infect; 2012 Feb; 18(2):189-94. PubMed ID: 21729194
[TBL] [Abstract][Full Text] [Related]
7. Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients.
Bochennek K; Tramsen L; Schedler N; Becker M; Klingebiel T; Groll AH; Lehrnbecher T
Clin Microbiol Infect; 2011 Dec; 17(12):1868-74. PubMed ID: 21895857
[TBL] [Abstract][Full Text] [Related]
8. Incidence of invasive fungal disease after unmanipulated haploidentical stem cell transplantation was significantly higher than that after HLA-matched sibling transplantation.
Sun Y; Xu L; Liu D; Zhang X; Han W; Wang Y; Chen H; Chen Y; Wang F; Wang J; Ji Y; Tang F; Liu K; Huang XJ
Clin Microbiol Infect; 2013 Nov; 19(11):1029-34. PubMed ID: 23565830
[TBL] [Abstract][Full Text] [Related]
9. Preventing invasive fungal disease in patients with haematological malignancies and the recipients of haematopoietic stem cell transplantation: practical aspects.
Akan H; Antia VP; Kouba M; Sinkó J; Tănase AD; Vrhovac R; Herbrecht R
J Antimicrob Chemother; 2013 Nov; 68 Suppl 3():iii5-16. PubMed ID: 24155144
[TBL] [Abstract][Full Text] [Related]
10. [Invasive fungal disease in hemato-oncological and hematopoietic stem cell transplantation patients from Hospital Clinico Universidad Católica, Santiago-Chile using revised EORTC/MSG diagnostic criteria].
Rabagliati B R; Fuentes L G; Guzmán D AM; Orellana U E; Oporto C J; Aedo C I; Garrido S M; Nervi N B
Rev Chilena Infectol; 2009 Jun; 26(3):212-9. PubMed ID: 19621153
[TBL] [Abstract][Full Text] [Related]
11. Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil.
Nucci M; Garnica M; Gloria AB; Lehugeur DS; Dias VC; Palma LC; Cappellano P; Fertrin KY; Carlesse F; Simões B; Bergamasco MD; Cunha CA; Seber A; Ribeiro MP; Queiroz-Telles F; Lee ML; Chauffaille ML; Silla L; de Souza CA; Colombo AL
Clin Microbiol Infect; 2013 Aug; 19(8):745-51. PubMed ID: 23009319
[TBL] [Abstract][Full Text] [Related]
12. Invasive fungal disease in allogeneic hematopoietic stem cell transplant recipients: an autopsy-driven survey.
Sinkó J; Csomor J; Nikolova R; Lueff S; Kriván G; Reményi P; Bátai A; Masszi T
Transpl Infect Dis; 2008 Apr; 10(2):106-9. PubMed ID: 17605727
[TBL] [Abstract][Full Text] [Related]
13. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study.
Lerolle N; Raffoux E; Socie G; Touratier S; Sauvageon H; Porcher R; Bretagne S; Bergeron A; Azoulay E; Molina JM; Lafaurie M
Clin Microbiol Infect; 2014 Nov; 20(11):O952-9. PubMed ID: 24861577
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
[TBL] [Abstract][Full Text] [Related]
15. Galactomannan in bronchoalveolar lavage for diagnosing invasive fungal disease.
Affolter K; Tamm M; Jahn K; Halter J; Passweg J; Hirsch HH; Stolz D
Am J Respir Crit Care Med; 2014 Aug; 190(3):309-17. PubMed ID: 25007380
[TBL] [Abstract][Full Text] [Related]
16. Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis.
Montesinos P; Rodríguez-Veiga R; Boluda B; Martínez-Cuadrón D; Cano I; Lancharro A; Sanz J; Arilla MJ; López-Chuliá F; Navarro I; Lorenzo I; Salavert M; Pemán J; Calvillo P; Martínez J; Carpio N; Jarque I; Sanz GF; Sanz MA
Bone Marrow Transplant; 2015 Nov; 50(11):1465-72. PubMed ID: 26281032
[TBL] [Abstract][Full Text] [Related]
17. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.
De la Serna J; Jarque I; López-Jiménez J; Fernández-Navarro JM; Gómez V; Jurado M; Pascual A; Serrano J; Romero M; Vallejo C
Rev Esp Quimioter; 2013 Mar; 26(1):64-9. PubMed ID: 23546466
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.
Vehreschild MJ; von Bergwelt-Baildon M; Tran L; Shimabukuro-Vornhagen A; Wisplinghoff H; Bangard C; Cornely OA; Vehreschild JJ
Eur J Haematol; 2014 Nov; 93(5):400-6. PubMed ID: 24798021
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of invasive fungal infections and rationale for antifungal therapy in patients with haematological malignancies.
Hoenigl M; Zollner-Schwetz I; Sill H; Linkesch W; Lass-Flörl C; Schnedl WJ; Krause R
Mycoses; 2011 Sep; 54(5):454-9. PubMed ID: 20406398
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation.
Kolve H; Ahlke E; Fegeler W; Ritter J; Jürgens H; Groll AH
J Antimicrob Chemother; 2009 Aug; 64(2):383-7. PubMed ID: 19491205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
